| Field | Specification |
|---|---|
| Target | |
| Alternative names | Vascular endothelial growth factor receptor 3; VEGFR-3; 2.7.10.1; Fms-like tyrosine kinase 4; FLT-4; Tyrosine-protein kinase receptor FLT4; FLT4; VEGFR3; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthetic peptide corresponding to a sequence at the N-terminus of human VEGF Receptor 3, which shares 82.8% and 79.3% amino acid (aa) sequence identity with mouse and rat VEGF Receptor 3, respectively. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets vascular endothelial growth factor receptor 3 (gene FLT4) in human, mouse and rat samples and is validated for flow cytometry, ICC/IF, IHC and Western blot. The predicted molecular weight is 152.8 kDa, and the supplier reports an observed band at about 153 kDa.
Vascular endothelial growth factor receptor 3 (VEGFR-3, FLT4) is a receptor tyrosine kinase activated by VEGF-C and VEGF-D. It is essential for the growth of lymphatic vessels and also contributes to early blood vessel development. VEGFR-3 is a common lymphatic endothelial marker, and FLT4 mutations cause hereditary lymphedema (Milroy disease).
| Target | Vascular endothelial growth factor receptor 3 (gene FLT4; UniProt P35916, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.05 mg NaN3; plus stabilizers |
| Calculated MW | 152.8 kDa |
| Observed MW | 153 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL |
|---|---|
| IHC (paraffin sections) | 0.5–1 µg/mL |
| IHC (frozen sections) | 0.5–1 µg/mL |
| Immunocytochemistry / Immunofluorescence | 2 µg/mL |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells |
Samples with a confirmed band (WB): human HeLa cells, human MCF-7 cells, human HepG2 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 50 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL, HRP-conjugated secondary antibody at 1:10000, ECL detection.
Samples with confirmed staining (IHC): human colon cancer tissue, human lung cancer tissue, human placenta tissue, human prostatic cancer tissue, mouse liver tissue, rat liver tissue, human mammary cancer tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in citrate buffer (pH 6).
Samples with confirmed staining (ICC/IF): A431 cells.
Samples with a confirmed signal (flow cytometry): U2OS cells.
Immunogen
Synthetic peptide from the N-terminal region of human VEGF Receptor 3. Sequence identity with the mouse and rat orthologs: 82.8% and 79.3%, respectively.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places vascular endothelial growth factor receptor 3 in the cell membrane, cytoplasm and nucleus. Tissue expression noted by UniProt (human): Detected in endothelial cells (at protein level). The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Yuzhu Zhou et al. (2025) Targeted Glioma Therapy via TMVP1 Peptide-Modified FLT4 Liposomes: A Novel Molecular Probe Strategy. International Journal of Nanomedicine. 10.2147/IJN.S517222
Wang Xiaoting et al. (2023) Downregulation of ITGA5 inhibits lymphangiogenesis and cell migration and invasion in male laryngeal squamous cell carcinoma. Protoplasma. 10.1007/s00709-023-01873-3
